Newsroom

伦敦和加州卡平特里亚--(BUSINESS WIRE)--(美国商业资讯)-- 全球领先的建筑管理软件供应商Procore Technologies, Inc. (NYSE: PCOR)今日宣布推出其互联公共数据环境(Common Data Environment, CDE)。这是一款在单一平台上从零打造的专用CDE，旨在统一并验证从审定设计到交付阶段的项目数据，在工作流中捕捉凭证，以帮助确保数字化记录与工地实际情况保持一致。这一可信的数据基石使得智能体AI能够跨越整个建筑生命周期发挥作用。 在这样一个由于信息碎片化而持续减缓决策速度、并导致高昂延误成本的行业中，互联数据正日益成为顶尖企业的核心竞争力。来自Dodge Construction Network*的最新研究发现，拥有经优化数据管理实践的企业，其生产率最高可提升23%，在使用相同资源的情况下可多管理27.8%的建筑体量，并将项目延误减少6天以上。这些企业还报告了高达40%的整体业绩增长，凸显了为什么一个可信的数据基石正在成为引入AI、提高运营效率以及最终实现更好项目执行的必备条件。 Procore的互联CDE正是为直面这一挑...

TAIPEI, Taiwan--(BUSINESS WIRE)--COMPUTEX — Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced a collaboration with Intel to enable AI PCs to deploy larger, more capable AI applications locally. The collaboration combines Intel® Core™ Ultra Series 3 processors with Phison’s Pascari aiDAPTIV, a memory extension solution that unblocks memory-constrained systems to support larger Mixture-of-Experts (MoE) AI models, longer-running AI sessio...

韓国ソウル--(BUSINESS WIRE)--ソウル半導体は世界初となる高電圧光半導体技術が、グローバルトップ自動車メーカー4社に採用され、本格的な量産を開始したと発表した。...

SAN FRANCISCO--(BUSINESS WIRE)--SNOWFLAKE SUMMIT 26--Snowflake (NYSE: SNOW), the AI Data Cloud company, and Anthropic, the AI safety and research company, today announced at Snowflake Summit 26 significant momentum in their strategic partnership. Enterprises are increasingly adopting Anthropic Claude in Snowflake Cortex AI, Snowflake’s suite of AI products, driven by growing demand for governed, production-ready AI. Together, Snowflake and Anthropic are helping enterprises move from AI experime...

TAIPEI, Taiwan--(BUSINESS WIRE)--Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced a new strategic initiative at COMPUTEX 2026 under the theme “AI Enabler: Evolving Data Storage Intelligence.” Expanding beyond its role as a storage technology leader, Phison is taking a systems-level approach to AI solutions spanning AI infrastructure, edge AI computing and AI software platforms. At COMPUTEX 2026, Phison is showcasing comprehensive AI s...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE:PHR) investors of the July 13, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Phreesia securities between May 8, 2025 through March 30, 2026 (“the Class Period”).Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the litigation on behalf of the...

PARIS--(BUSINESS WIRE)--Today at the Choose France Summit, created by the President of the French Republic, Emmanuel Macron, Vast announced its commitment to establish its European headquarters in Paris and an agreement with the Government of France, for two missions involving two French astronauts: the sixth private astronaut mission to the International Space Station and the Haven-1 test flight, the first crewed mission to Vast’s Haven-1 commercial space station scheduled to launch in 2027. F...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) securities during the period of February 25, 2026 through April 13, 2026, inclusive (“the Class Period”).If you suffered a loss on your Lucid investments, you have until July 28, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID...

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer). The results were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. In this stu...